Department of Medical and Surgical Specialties and Dentistry, Second University of Naples, Naples, Italy,
Aging Clin Exp Res. 2013 Oct;25 Suppl 1:S137-41. doi: 10.1007/s40520-013-0127-5. Epub 2013 Sep 18.
The aim of our retrospective cohort study is to analyze the persistence rates in relation to antiosteoporotic drugs using administrative databases in the Campania Region. Patients, aged ≥40 years, were included if at least one prescription for any antiosteoporotic drugs had been filled in between January 1, 2009 and December 31, 2009. Overall, 37,594 patients were incident users of antiosteoporotic drugs. Among them, 15,978 patients had undergone spot-therapies. A total of 2,618 (14.1%) were classified as switchers. Switching rates were highest for patients taking Alendronate 18.9 or Strontium Ranelate 15.0 and lower for patients taking Ibandronate 12.8 or Risedronate 10.8. In the overall population, 33.5% of subjects were still on therapy after 6 months. At 1 year, persistence rates were: Ibandronate 21.6%, Risedronate 15.8%, Alendronate + Vitamin D 15.7%, Raloxifene 14.3%, Alendronate 12.6% and Strontium Ranelate 5.0%.
我们的回顾性队列研究旨在使用坎帕尼亚地区的行政数据库分析与抗骨质疏松药物相关的持续率。患者年龄≥40 岁，如果在 2009 年 1 月 1 日至 2009 年 12 月 31 日之间至少开了一种抗骨质疏松药物处方，则将其纳入研究。共有 37594 名患者为新使用抗骨质疏松药物的患者。其中，15978 名患者进行了定点治疗。共有 2618 名（14.1%）患者被归类为换药者。使用阿仑膦酸钠 18.9 或雷奈酸锶 15.0 的患者的换药率最高，而使用伊班膦酸盐 12.8 或利塞膦酸盐 10.8 的患者的换药率较低。在总体人群中，33.5%的患者在 6 个月后仍在接受治疗。在 1 年内，持续率为：伊班膦酸盐 21.6%，利塞膦酸盐 15.8%，阿仑膦酸钠+维生素 D 15.7%，雷洛昔芬 14.3%，阿仑膦酸钠 12.6%和雷奈酸锶 5.0%。
